Symbiotix Biotherapies’s exclusive license agreement with Harvard University

Choate recently represented Symbiotix Biotherapies, Inc. (Symbiotix), a pioneering venture-backed biotechnology company developing novel molecular therapeutics derived from the human microbiome, in negotiating its exclusive license…

This content is for Standard 1 Year members only.
Login Join Now
Avatar

Author: Ambrogio Visconti

This content is for Standard 1 Year members only.
Login Join Now